Prescription digital therapeutics (DTx)—software applications designed to prevent, manage, or treat medical disorders—are demonstrating strong clinical efficacy. However, commercial expansion remains constrained by fragmented reimbursement structures across major healthcare systems.
Reimbursement Friction
While regulatory bodies have cleared numerous digital software treatments for neurological and metabolic conditions, insurers lack standardized frameworks for coverage. Providers face high administrative overhead when submitting claims for non-traditional software therapies.
Payer Requirements
Health insurers are demanding real-world evidence (RWE) proving that software treatments reduce overall healthcare utilization costs. Companies in the space are increasingly partnering with pharmaceutical firms to leverage established distribution and billing networks.